https://www.selleckchem.com/pr....oducts/conteltinib-c
Both ciclosporin and infliximab were significantly more efficacious than placebo in achieving a response. Neither treatment was more effective than placebo for inducing remission, nor more likely to cause serious adverse events than placebo. Both ciclosporin and infliximab were superior to placebo in terms of response to therapy and avoiding colectomy up to 1 year, with no significant differences in efficacy or safety between the two. Ciclosporin is still a valid option to treat refractory UC patients, especially those who do
Like
Comment
Share
